News Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 20:00:00 13/03/2026 GMT			5-day change	1st Jan Change
144.99 ^USD	+0.42%		+0.74%	+18.13%

03-11	Gilead Sciences, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-11-2026 11:00 AM
03-10	Gilead Sciences, Inc. Presents at Leerink Global Healthcare Conference 2026, Mar-10-2026 11:20 AM

All News

03-12		FA
03-11	Gilead Sciences, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-11-2026 11:00 AM
03-10	Gilead Sciences, Inc. Presents at Leerink Global Healthcare Conference 2026, Mar-10-2026 11:20 AM
03-09	IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, Potential PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update	CI
03-09	Global drugmakers rush to boost US presence as tariff threat looms	RE
03-09	Bringing It Home - South Africa is Leading the Charge to Make Anti-HIV jab for Africa	AQ
03-09	Lyell Immunopharma, Inc. Appoints Smital Shah as Chief Business Officer and Principal Financial Officer, Effective March 9, 2026	CI
03-09	Lyell Immunopharma, Inc. Announces Chief Financial Officer Changes	CI
03-09	Ideaya Biosciences Says 1st Patient Enrolled in Phase 1 Clinical Trial of Solid Tumors; Shares Up Pre-Bell	MT
03-06	Gilead Sciences' HIV Drug Eyed for Local Production by South Africa	MT
03-05	The Year the Easy Narrative Broke
03-05	South Africa seeks local production of Gilead's HIV prevention drug	RE
03-04	Citius Oncology, Inc. Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR Dosing Prior to Commercial CAR-T Therapy in High-Risk Diffuse Large B-Cell Lymphoma	CI
03-03	Gilead Sciences, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 11:10 AM
03-02	Gilead Sciences Insider Sold Shares Worth $1,447,859, According to a Recent SEC Filing	MT
03-02	Gilead Foundation awards $12 million to empower community health workers and expand HIV prevention initiatives across 14 states and the District of Columbia	RE
03-02	Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia	BU
03-02	United Therapeutics' drug slows progression of rare lung condition in late-stage study	RE
02-27	MBX Biosciences, Inc. Announces CFO Changes	CI
02-25	Arcus Biosciences Provides Pipeline Update on Its Clinical-Stage Investigational Molecules and Discovery Programs	CI
02-25	Gilead Sciences, Inc. Announces the Presentation of New Phase 3 ARTISTRY-1 and ARTISTRY-2 Trial Data At CROI 2026	CI
02-25	Gilead's experimental HIV treatment shows low discontinuation rates in studies	RE
02-25	Gilead Says HIV Treatment Trial Results Show Efficacy	DJ
02-25	Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy	BU
02-25	Daiwa Securities Adjusts Price Target on Gilead Sciences to $161 From $129, Maintains Outperform Rating	MT